PT  - JOURNAL ARTICLE
AU  - Kim, Tae Min
AU  - Ngamphaiboon, Nuttapong
AU  - Lee, Ki Hyeong
AU  - Desai, Pratibha
AU  - Lin, Chia-Chi
AU  - Muzaffar, Jameel
AU  - Feng, Yin-Hsun
AU  - Wu, Shang-Yin
AU  - Brahmer, Julie
AU  - Chisamore, Michael
AU  - Kassner, Paul D
AU  - Brockstedt, Dirk G
AU  - Goyal, Rakesh Kumar
AU  - Nasrah, Nicole
AU  - Ho, William
TI  - 629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoint inhibitor
AID  - 10.1136/jitc-2023-SITC2023.0629-C
DP  - 2023 Nov 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - A1808--A1808
VI  - 11
IP  - Suppl 2
4099  - http://jitc.bmj.com/content/11/Suppl_2/A1808.short
4100  - http://jitc.bmj.com/content/11/Suppl_2/A1808.full
SO  - J Immunother Cancer2023 Nov 01; 11
AB  - Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.